The Value of ctDNA on Chemotherapy Efficacy for mCRC

Launched by FUDAN UNIVERSITY · Sep 15, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how well a specific test called ctDNA (circulating tumor DNA) can predict how effective chemotherapy will be for patients with advanced colorectal cancer that has spread to other parts of the body. By examining ctDNA, researchers hope to find a better way to tailor treatments for patients, potentially leading to more successful outcomes.

To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of advanced colorectal cancer. You should be in decent health, with a life expectancy of at least three months, and have one or more measurable areas of cancer spread. However, if you have certain conditions like chronic bowel diseases or serious infections, you may not qualify. If you join the study, you will undergo tests to assess your ctDNA and receive chemotherapy as part of your treatment, with the aim of helping doctors understand how to improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status of 0 to 2 life expectancy of ≥ 3 months at least one measurable metastatic lesion have adequate bone marrow, hepatic, and renal function
• Exclusion Criteria:
• • patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection